Swiss based global pharmacological company F.Hoffmann La Roche has participated in the series A round of Israel-based Ccam Biotherapeutics, a pre-clinic stage developer of immunotherapies for cancer. The amount raised was undisclosed.
The funding was led by Arkin Holdings, a drug specialist and manufacturer. The round also saw participation from Pontifax, a venture capital firm who seek to invest in the life sciences sector. Pontifax seeks to invest in companies based in Israel.
Chief executive of Ccam Bio, Tehila Ben Moshe, said: “With our series A complete, we are in the position to advance our lead antibody through a proof of concept study in humans.”